Cagrilintide is a 37-amino-acid acylated amylin analog with affinity at all five amylin receptor subtypes. Investigated by Novo Nordisk both as monotherapy and in combination with semaglutide (CagriSema).
Cagrilintide is a long-acting, acylated analog of amylin — the pancreatic hormone co-secreted with insulin that signals satiety and slows gastric emptying. It binds across the amylin and calcitonin receptor subtypes and carries a fatty-acid chain that supports once-weekly dosing.
Developed by Novo Nordisk, it is investigational and studied both on its own and in a fixed combination with semaglutide known as CagriSema, where the amylin and GLP-1 pathways are paired for additive weight effect.
Amylin and calcitonin receptor agonism → satiety, slowed gastric emptying.
Behind every vial of Cagrilintide is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how Cagrilintide, specifically, is brought into being.
On paper, Cagrilintide is C194H312N54O59S2 — about 4,409.2 daltons of precisely arranged atoms. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
Cagrilintide is assembled by solid-phase peptide synthesis — the chain grows one protected residue at a time on resin, and what you fail to build cleanly here you pay to remove later. It also carries fatty-acid acylation, an extra step beyond a plain chain that adds both capability and cost.
The crude mixture — Cagrilintide plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of Cagrilintide proves itself: identity confirmed by mass spectrometry against its ~4,409.2 Da, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of Cagrilintide — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
Producing Cagrilintide to a genuine purity spec means solid-phase synthesis, preparative HPLC purification, and batch quality control — none of it cheap, and none of it something you can verify by eye.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Recent clinical trials and publications mentioning Cagrilintide, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.
Cagrilintide is an investigational long-acting amylin analog studied for weight management, both alone and combined with semaglutide (CagriSema).
CagriSema is the investigational fixed combination of cagrilintide (amylin) and semaglutide (GLP-1), pairing two appetite pathways for additive effect.
Both promote satiety, but amylin acts through amylin and calcitonin receptors while GLP-1 acts through the GLP-1 receptor; combining them is studied for complementary effects.
No — it is investigational. This page is a research and educational reference.
Dosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.